These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30467067)

  • 1. Allogeneic hematopoietic cell transplantation; the current renaissance.
    Copelan EA; Chojecki A; Lazarus HM; Avalos BR
    Blood Rev; 2019 Mar; 34():34-44. PubMed ID: 30467067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Use and Trends in Hematopoietic Cell Transplantation in the United States.
    D'Souza A; Lee S; Zhu X; Pasquini M
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1417-1421. PubMed ID: 28606646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonmyeloablative allogeneic hematopoietic cell transplantation.
    Storb R; Sandmaier BM
    Haematologica; 2016 May; 101(5):521-30. PubMed ID: 27132278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stem-cell dose for allogeneic hematopoietic stem cell transplantation in hematological malignancies: is more better?
    Shimoni A; Nagler A
    Leuk Lymphoma; 2009 Sep; 50(9):1395-6. PubMed ID: 19672777
    [No Abstract]   [Full Text] [Related]  

  • 7. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
    van Besien K; Hari P; Zhang MJ; Liu HT; Stock W; Godley L; Odenike O; Larson R; Bishop M; Wickrema A; Gergis U; Mayer S; Shore T; Tsai S; Rhodes J; Cushing MM; Korman S; Artz A
    Haematologica; 2016 May; 101(5):634-43. PubMed ID: 26869630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.
    Haen SP; Groh C; Schumm M; Backert L; Löffler MW; Federmann B; Faul C; Dörfel D; Vogel W; Handgretinger R; Kanz L; Bethge WA
    Ann Hematol; 2017 May; 96(5):817-827. PubMed ID: 28247058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic cell transplantation: the state of the art.
    Gyurkocza B; Rezvani A; Storb RF
    Expert Rev Hematol; 2010 Jun; 3(3):285-99. PubMed ID: 20871781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Allogeneic hematopoietic stem cell transplantations].
    Michallet M
    Transfus Clin Biol; 2011 Apr; 18(2):235-45. PubMed ID: 21466967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
    Kothari A; Ngwube A; Hayashi R; Murray L; Davis J; Haut P; Loechelt BJ; Shenoy S
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1321-5. PubMed ID: 25840334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
    Ghosh N; Karmali R; Rocha V; Ahn KW; DiGilio A; Hari PN; Bachanova V; Bacher U; Dahi P; de Lima M; D'Souza A; Fenske TS; Ganguly S; Kharfan-Dabaja MA; Prestidge TD; Savani BN; Smith SM; Sureda AM; Waller EK; Jaglowski S; Herrera AF; Armand P; Salit RB; Wagner-Johnston ND; Fuchs E; Bolaños-Meade J; Hamadani M
    J Clin Oncol; 2016 Sep; 34(26):3141-9. PubMed ID: 27269951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
    Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic stem cell transplantation for sickle cell disease.
    Robinson TM; Fuchs EJ
    Curr Opin Hematol; 2016 Nov; 23(6):524-529. PubMed ID: 27496639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders.
    Bhatt ST; Bednarski JJ
    Front Immunol; 2020; 11():1988. PubMed ID: 33013851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.
    Mehta RS; Peffault de Latour R; DeFor TE; Robin M; Lazaryan A; Xhaard A; Bejanyan N; de Fontbrune FS; Arora M; Brunstein CG; Blazar BR; Weisdorf DJ; MacMillan ML; Socie G; Holtan SG
    Haematologica; 2016 Jun; 101(6):764-72. PubMed ID: 27036159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies.
    Konuma T; Kato S; Oiwa-Monna M; Ishii H; Tojo A; Takahashi S
    Leuk Lymphoma; 2016 Sep; 57(9):2126-32. PubMed ID: 26769297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
    Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
    J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.
    Nakamura R; Forman SJ
    Expert Rev Hematol; 2014 Jun; 7(3):407-21. PubMed ID: 24702163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.